New $120M federal center would target U.S. biopharmaceutical manufacturing gaps

What does this do?

HR 6089 would establish a National Biopharmaceutical Manufacturing Center of Excellence administered through the National Institute of Standards and Technology (NIST). The center would focus on improving how the United States manufactures biopharmaceuticals, including vaccines, insulin, and cancer treatments made from living cells or biological organisms. It would also help move new manufacturing methods from laboratory research to large-scale commercial production and share findings with federal agencies and the public.

Who does it affect?

Workers in biotechnology and pharmaceutical industries would be directly affected, as the bill includes funding for job training programs in those fields. American drug and biotech companies, particularly smaller ones working to scale up products, would have access to the center's shared research and facilities.

Why does it matter?

The bill is aimed at making the United States more self-sufficient in producing medicines and reducing reliance on foreign manufacturing for supplies and equipment. Bridging the gap between laboratory-stage innovation and large-scale commercial production is identified as one of the biggest current challenges for American biotech companies.

What does it cost, and who pays?

The federal government would award up to $120 million to a single qualifying organization, which could be a university, a public-private partnership, or a group of such entities working together.

Where does it stand?